Sphere Fluidics strengthens global commercial teams and establishes direct sales and support channel in North America

Sphere Fluidics announces Cyto-Mine Chroma to accelerate and streamline workflows across expanded applications in biotherapeutic discovery and development

Sphere Fluidics appoints Dr. Alex Dickinson as Non-Executive Director

Sphere Fluidics awarded Gold accreditation by Investors in People

Internationally-recognized ‘We invest in people’ award is certified recognition of the Company’s care and commitment to its employees globally

Sphere Fluidics launches Cyto-CellectPLUS to accelerate cell line development workflows

Next-generation assay provides a rapid and cost-effective solution to quantify IgG production in single cells

Sphere Fluidics wins The Life Science Company Of The Year Award from the Cambridge Independent

The Cambridge Independent awards were held on the 16th of May 2024, where we were proudly finalists for 2 very prestigious awards: 'Employer of the Year' and 'Life Science Company of the Year'. Being nominated for either of these awards is a great honor for all the team at Sphere Fluidics.

Sphere Fluidics appoints Curtis Nicholson as Director of Sales, EMEA, to support accelerated growth in key markets

Cambridge, UK, 23 May, 2024: Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the appointment of Curtis Nicholson as Directo

Sphere Fluidics appoints Dale Levitzke as Chief Executive Officer

Dale Levitzke joins as Dr. Frank F. Craig, current CEO and co-founder, announces his retirement after leading the Company for 14 years.

Sphere Fluidics appoints Edward Rayner as Non-Executive Director

Ed Rayner joins Sphere Fluidics as new board member to strengthen the Company’s strategic vision and ambition for commercial growth.

Sphere Fluidics appoints Dr. Graeme Daniels as Vice President of Sales and Marketing

Appointment to senior leadership team strengthens the Company’s plans for continued growth to advance its commercial ambitions

Sphere Fluidics’ Cyto-Mine system selected by FairJourney Biologics to advance cell line development workflows

Investment to expand cell line development capabilities and accelerate customer workflows, as part of its diverse and tailored antibody solutions.

Sphere Fluidics expands Cyto-Mine capabilities to meet cGMP requirements for drug manufacture workflows

Sphere Fluidics’ Pico-Mine platform chosen by Biosyntia to accelerate synthetic biology and metabolic workflows

Cambridge, UK, and Copenhagen, Denmark - Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announces Biosyntia, a biotechnology company focused on synthetic biology and metabolic engineering, has adopted the Pico-Mine® platform within its workflows.

Sphere Fluidics updates brand identity to align with ambitious, global commercial growth strategy

Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors.

Sphere Fluidics begins work with partners on 3DSecret program to investigate mechanisms of metastasis in cancer

Sphere Fluidics appoints Richard Hammond as Chief Technical Officer

Key appointment forms part of ongoing plans to strengthen senior leadership team and support expansion of microfluidic product range for single cell analysis

Sphere Fluidics opens new laboratory facilities at Granta Park in Cambridgeshire, UK

Cambridge, UK - Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announces that it has opened a new state-of-the-art facility in Granta Park, Cambridgeshire, UK, to support the Company’s growth. Doubling overall capacity, the laboratories enable the team’s accelerated expansion, and the development of new, innovative products.

Sphere Fluidics closes a $40 million funding round

Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million (circa £30 million) investment round. The round was led by Sofinnova Partners (Paris, France) and Redmile Group (San Francisco, USA) co-investing on equal terms.

Sphere Fluidics and ClexBio introduce CYTRIX Microfluidic Hydrogel Kit

Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, and ClexBio, a pioneer in solutions for tissue engineering and single-cell techniques, today announced the launch of the biocompatible CYTRIX Microfluidic Hydrogel Kit.

Sphere Fluidics announces enhanced Cyto-Mine capability and performance

Simplified design reduces manufacturing time and offers improved functionality to help streamline antibody discovery, cell line development, cell therapy, and synthetic biology workflows.

Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, and Heriot-Watt University, a specialist, pioneering Scottish University, today announced they have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency.

Sphere Fluidics receives Queen’s Award for Enterprise

Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, has be honored with a Queen’s Award for Enterprise for Innovation. The award recognises the Company’s excellence in patenting, developing and globally commercialising single cell analysis systems for biotherapeutic discovery.

Sphere Fluidics expands commercial operations to increase supply of Pico-Surf surfactant for droplet microfluidics

Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, today announced investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf™, for reliable and highly stable droplet generation and processing.

Sphere Fluidics and Peak Analysis and Automation introduce integrated micro-plate handling and single cell analysis capabilities

Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leading supplier of intelligent laboratory automation solutions, today announced the optimization of the Cyto-Mine® Single Cell Analysis System through integration with PAA’s automated plate handler, S-LAB™. The addition of S-LAB to…